PMID- 17145577
OWN - NLM
STAT- MEDLINE
DCOM- 20061218
LR  - 20110405
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 93
IP  - 11
DP  - 2006 Nov
TI  - [Neoadjuvant chemotherapy in non small cell lung cancer].
PG  - 1087-92
AB  - Standards of care for non small cell lung cancer (NSCLC) are not, yet, totally 
      established. The role of induction chemotherapy is still debated while it has 
      been established that adjuvant cisplatin based chemotherapy improve overall 
      survival in completely resected patients. We will review the feasibility and 
      efficacy of induction chemotherapy for patients with early-stage and locally 
      advanced NSCLC, particularly with N2 disease. In the neoadjuvant setting, a 32 to 
      60% response rate is awaited considering the high treatment compliance. Near to 
      10% pathologic complete response rate is reported. Nevertheless, no large 
      randomised phase III trial has demonstrated that induction chemotherapy could 
      prolong patients overall survival. Suboptimal cytotoxic combinations and an 
      increased surgical mortality might explain this result. Studies suggested that 
      patient's subgroups (as downstaged N2 disease) could benefit from induction 
      treatment. This still need to be confirmed in randomised trial and meta-analysis 
      based on individual data.
FAU - Besse, Benjamin
AU  - Besse B
AD  - Departement de medecine, Institut Gustave-Roussy, Villejuif. besse@igr.fr
FAU - Vignot, Stephane
AU  - Vignot S
FAU - Le Chevalier, Thierry
AU  - Le Chevalier T
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Traitements neoadjuvants des cancers bronchiques non a petites cellules.
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/surgery
MH  - Chemotherapy, Adjuvant/methods
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology/surgery
MH  - Neoadjuvant Therapy/*methods
RF  - 49
EDAT- 2006/12/06 09:00
MHDA- 2006/12/19 09:00
CRDT- 2006/12/06 09:00
PHST- 2006/10/16 00:00 [received]
PHST- 2006/10/23 00:00 [accepted]
PHST- 2006/12/06 09:00 [pubmed]
PHST- 2006/12/19 09:00 [medline]
PHST- 2006/12/06 09:00 [entrez]
PST - ppublish
SO  - Bull Cancer. 2006 Nov;93(11):1087-92.